Literature DB >> 9179515

Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts.

K Miotto1, M J McCann, R A Rawson, D Frosch, W Ling.   

Abstract

In a study evaluating naltrexone with either an intensive psychosocial protocol or standard community treatment for opioid dependence, 13 of 81 subjects overdosed within a 12-month period of study participation. There were four fatalities, one of which was a suicide. Among the nine nonfatal overdoses, there were four suicide attempts. Characteristics of subjects and naltrexone-taking are described.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9179515     DOI： 10.1016/s0376-8716(97)01348-3

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN： 0376-8716            Impact factor:   4.492


  16 in total

1.  Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement.

Authors:  K M Carroll; S A Ball; C Nich; P G O'Connor; D A Eagan; T L Frankforter; E G Triffleman; J Shi; B J Rounsaville
Journal:  Arch Gen Psychiatry       Date:  2001-08

Review 2.  Clinical safety of 1500 mg oral naltrexone overdose.

Authors:  Albert Stuart Reece
Journal:  BMJ Case Rep       Date:  2010-09-07

3.  Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.

Authors:  Paolo Mannelli; Li-Tzy Wu; Kathleen S Peindl; Marvin S Swartz; George E Woody
Journal:  Drug Alcohol Depend       Date:  2014-02-15       Impact factor: 4.492

4.  Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial.

Authors:  Richard S Schottenfeld; Marek C Chawarski; Mahmud Mazlan
Journal:  Lancet       Date:  2008-06-28       Impact factor: 79.321

5.  Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence.

Authors:  Angela J Dean; John B Saunders; Rod T Jones; Ross M Young; Jason P Connor; Bruce R Lawford
Journal:  J Psychiatry Neurosci       Date:  2006-01       Impact factor: 6.186

6.  Management of relapse in naltrexone maintenance for heroin dependence.

Authors:  Maria A Sullivan; Fatima Garawi; Adam Bisaga; Sandra D Comer; Kenneth Carpenter; Wilfrid N Raby; Stephen J Anen; Adam C Brooks; Huiping Jiang; Evaristo Akerele; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2007-08-02       Impact factor: 4.492

Review 7.  Injectable and implantable sustained release naltrexone in the treatment of opioid addiction.

Authors:  Nikolaj Kunøe; Philipp Lobmaier; Hanh Ngo; Gary Hulse
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

8.  Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder.

Authors:  Kathleen M Carroll; Charla Nich; Tami L Frankforter; Sarah W Yip; Brian D Kiluk; Elise E DeVito; Mehmet Sofuoglu
Journal:  Drug Alcohol Depend       Date:  2018-10-04       Impact factor: 4.492

9.  Illicit opioid intoxication: diagnosis and treatment.

Authors:  A Fareed; S Stout; J Casarella; S Vayalapalli; J Cox; K Drexler
Journal:  Subst Abuse       Date:  2011-04-18

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.